Research Article

Urine Bikunin as a Marker of Renal Impairment in Fabry’s Disease

Antonio Junior Lepedda,1 Laura Fancellu,2 Elisabetta Zinellu,1 Pierina De Muro,1 Gabriele Nieddu,1 Giovanni Andrea Deiana,2 Piera Canu,2 Daniela Concolino,3 Simona Sestito,3 Marilena Formato,1 and Gianpietro Sechi2

1 Dipartimento di Scienze Biomediche, University of Sassari, Via Muroni 25, 07100 Sassari, Italy
2 Dipartimento di Medicina Clinica e Sperimentale, University of Sassari, Viale San Pietro 10, 07100 Sassari, Italy
3 Unità Operativa di Pediatria Universitaria, Azienda Ospedaliera “Pugliese-Ciaccio”, Viale Pio X, 88100 Catanzaro, Italy

Correspondence should be addressed to Antonio Junior Lepedda; ajlepedda@uniss.it and Gianpietro Sechi; gpsechi@uniss.it

Received 22 February 2013; Revised 2 May 2013; Accepted 20 May 2013

1. Introduction

Fabry’s disease (FD) is a panethnic, X-linked lysosomal storage disorder due to deficiency of α-galactosidase A [1]. This lysosomal enzyme normally breaks down neutral glycosphingolipids, particularly globotriaosylceramide (Gb3), catalyzing the hydrolytic cleavage of the terminal molecule of galactose. The consequent accumulation of these glycosphin-golipids in many cell types and tissues results in several clinical signs and symptoms [1]. The prevalence of Fabry’s disease has been estimated to range from 1 in 117,000 to up to 1 in 40,000, but it might be much higher since it is likely that many patients are not identified, because of either the nonspecificity of clinical features or the scarce suspicion of the clinician for the disease [1]. The α-galactosidase A gene (GLA-gene) is located on the long arm of chromosome X in position Xq22, and it has recently been sequenced [1]. More than 400 mutations have been identified so far. Depending on the type of mutation there may be different clinical forms of the disease. In particular, GLA-gene mutations resulting in a total absence of α-galactosidase A activity usually lead to a more severe form of FD [1]. Disease manifestations usually start in childhood, with intermittent acroparesthesias, sometimes associated with episodic fever, hypohidrosis, gastrointestinal symptoms, typical vascular skin lesions named angiokeratomas, and corneal opacities [2]. After the 3rd decade of life the progression of the pathology frequently leads to renal damage [3], cardiac manifestations, and high propensity to develop brain ischemic stroke, resulting in decreased life expectancy [4]. In particular, end-stage renal disease, with proteinuria and progressive renal failure, is a major cause of morbidity and mortality in FD. Renal damage seems mainly
to be caused by diffuse deposition of glycosphingolipids in glomeruli, tubular system, and vasculature. In routine clinical practice, general proteinuria and microalbuminuria are considered the best biomarkers of FD nephropathy [3], although, recently, many new markers, including Gb3 or specific proteins such as N-acetyl-β-D-glucosaminidase and cystatin C, have been suggested to improve decision making [5]. However, the efficacy of all of the biomarkers currently in use for Fabry's nephropathy remains uncertain.

Several studies evidenced variations in plasma/urine glycosaminoglycans in physiological and pathological conditions. Glycosaminoglycans (GAGs) are linear and complex polysaccharides, composed of a variable number of repeating disaccharide units, each containing a hexuronic acid glycosidically linked to a hexosamine residue. GAGs have been found in many tissues and in biological fluids such as blood, plasma and urine [6]. Plasma GAGs represent components of intact proteoglycans (PGs) mainly of hepatic and endothelial origin, secreted into blood as well as products of tissue PG degradation. Chondroitin sulfate (CS), the main GAG type in plasma, is derived from both the cell surfaces and the extracellular matrix. A portion of CS is covalently bound to a protein core to form bikunin that is principally synthesized and secreted by the liver [7]. CS chains are short, consisting of 12–18 disaccharides units, and present a charge density of about 30–40% as previously reported [8, 9]. Most of circulating bikunin is present as the light chain of Inter-α-Inhibitor (IαI) family molecules [10]. Bikunin is a serine protease inhibitor and it occurs in plasma as well as in many tissues [10]. It is also excreted in urine and referred to as urinary trypsin inhibitor (UTI). In urine, GAGs consist mainly of heparan sulfate (HS), CS, and, in negligible quantity, dermatan sulfate [6]. In the general population, bikunin has been reported to occur at higher levels in various pathological conditions exhibiting chronic inflammation, including cancer [11], chronic glomerulonephritis [12, 13], kidney transplantation [14], type I diabetes [15], and systemic lupus erythematosus [16]. Moreover, we reported variations of urine bikunin levels during the physiological menstrual cycle in fertile women [17]. It has also been suggested that bikunin may be a useful marker for renal damage [18], liver disease [19], and brain contusion [20], suggesting a potential application in patients with FD. Since kidney damage is a frequent and severe complication of FD, we thought of evaluating plasma and urine GAGs levels in this pathology to assess if their urinary excretion could represent a useful early marker of kidney impairment in patients with Fabry's disease.

2. Methods

2.1. Samples. Analyses were conducted on fasting blood-plasma and first-morning urine samples from 24 Fabry's patients of both sexes, aged from 20 to 61 years, and 43 age- and gender-matched healthy controls. All FD patients were diagnosed by identifying the mutation in the GLA-gene and showed reduced activity of α-galactosidase A enzyme in plasma (Table 1). Among patients, 13 did not present evidence of chronic renal damage (NRD); the other 11, instead, presented, for more than 3 months, pathological abnormalities indicative of chronic renal damage (RD), including abnormalities in blood or urine tests (i.e., serum creatinine; proteinuria/microalbuminuria; and abnormalities in urine sediment) or imaging studies (e.g., renal ultrasound). More in detail, 5 RD patients presented with only proteinuria, whereas 6 presented with overt renal damage. In both FD patients and controls the serum levels of three classic markers of inflammation such as erythrocyte sedimentation rate (ESR) (by means of stopped flow capillary microspectrophotometry), C-reactive protein (CRP) (by means of chemiluminescence assay), and α1- and α2-globulins (by means of capillary electrophoresis) were evaluated. Informed consent was obtained before enrolment. Institutional review board approval was obtained. The study was conducted in accordance with the ethical principles of the current Declaration of Helsinki.

2.2. Plasma CS Isomers Analysis. GAGs isolation was performed by a microanalytic preparative method, as previously described [8]. Briefly, 500 μL of plasma samples was subjected to proteolytic treatment with papain. Plasma CS isomers were isolated by anion exchange chromatography (DEAE-Sephalac) and precipitated with 5 volumes of ethanol at −20°C for 24 h. Subsequently, they were subjected to depolymerization by using chondroitin ABC lyase (0.1U per 100 μg hexuronic acid), and the unsaturated disaccharides were derivatized with 12.5 nmol/L 2-aminoacridone (AMAC).

Separation of CS-derived unsaturated disaccharides (ΔDi) was performed by fluorophore-assisted carbohydrate electrophoresis (FACE). Images were acquired by means of Gel Doc XR system (Bio-Rad) and analyzed by using Quantity One v4.6.3 software (Bio-Rad). A calibration curve was set up by using home-made CS isomers obtained from a pool of plasma samples, assayed for hexuronate content [21], and subjected to disaccharides analysis [8]. CS levels were reported as μg of hexuronic acid per mL of plasma (μgUA/mL), and CS charge density was evaluated as ratio between 4-sulfated Δ-disaccharides (ΔDi-4S) and total unsaturated disaccharides (ΔDi-4S + ΔDi-nonS).

2.3. Urine GAGs/Bikunin Analysis. First-morning urine samples (about 50 mL) were collected and, after centrifugation at 3000 g for 15 min at 4°C, the sediment of broken cells or tissues and other solid materials was discarded. Urine GAGs/bikunin containing fraction was obtained by anion exchange chromatography (DEAE-Sephadex resin) as previously described [15]. Briefly, clarified urines were applied to a column packed with about 6 mL of resin, previously equilibrated with a buffer containing 0.02 M Tris-HCl, 0.15 M NaCl (pH 8.6). After exhaustive washing, urinary GAGs/bikunin were eluted with a buffer containing 0.02 M Tris-HCl, 2 M LiCl (pH 8.6), and assayed for hexuronate content by the method of Bitter and Muir, using glucuronic acid as a standard [21]. Hexuronate levels were normalized for the urinary creatinine concentration, formerly determined by the Jaffé method (Sentinel CH, Milan, Italy). Urinary GAGs/bikunin composition was determined by discontinuous electrophoresis on cellulose
Table 1: Clinical and genetic features of Fabry’s patients.

| Patient | Age | Gender | Renal involvement | GLA mutations | α-galactosidase A (nmol/mL/h)* | ERT |
|---------|-----|--------|------------------|---------------|-----------------------------|-----|
| 1       | 59  | F      | RD               | Cys172Tyr     | 1.70                        | Y   |
| 2       | 26  | F      | RD               | Cys172Tyr     | 4.68                        | Y   |
| 3       | 30  | M      | NRD              | Cys172Tyr     | 3.70                        | Y   |
| 4       | 38  | M      | NRD              | Cys172Tyr     | 5.30                        | Y   |
| 5       | 33  | M      | proteinuria      | Cys172Tyr     | 2.80                        | Y   |
| 6       | 27  | M      | RD               | Cys172Tyr     | 3.40                        | Y   |
| 7       | 46  | F      | RD               | 846,847delTC  | 3.50                        | Y   |
| 8       | 24  | F      | proteinuria      | 846,847delTC  | 3.50                        | Y   |
| 9       | 20  | F      | proteinuria      | 846,847delTC  | 3.30                        | Y   |
| 10      | 58  | M      | RD               | 846,847delTC  | 3.90                        | Y   |
| 11      | 36  | M      | proteinuria      | 846,847delTC  | 0.48                        | Y   |
| 12      | 36  | F      | NRD              | Arg112His     | 2.80                        | N   |
| 13      | 61  | F      | NRD              | Gln57Arg      | 11.10                       | N   |
| 14      | 62  | F      | NRD              | Gln57Arg      | 14.80                       | N   |
| 15      | 23  | F      | NRD              | Gln57Arg      | 10.40                       | N   |
| 16      | 58  | F      | NRD              | Asp313Tyr     | 9.80                        | Y   |
| 17      | 53  | F      | NRD              | Arg227Gln     | 8.10                        | N   |
| 18      | 52  | F      | NRD              | Arg227Gln     | 2.50                        | Y   |
| 19      | 31  | M      | NRD              | Arg227Gln     | 0.10                        | Y   |
| 20      | 42  | M      | RD               | Arg227Gln     | 0.70                        | Y   |
| 21      | 32  | M      | proteinuria      | Arg227Gln     | 2.50                        | Y   |
| 22      | 19  | F      | NRD              | Arg227Gln     | 6.60                        | Y   |
| 23      | 43  | F      | NRD              | IVS3+G>A      | 9.70                        | Y   |

NRD: no-renal disease; RD: renal disease; ERT: enzyme replacement therapy; Y: under ERT therapy; N: no ERT therapy.

*At the time of diagnosis.

acetate plates [12–17], according to Cappelletti et al. [22]. Analytes were resolved by three electrophoretic steps in 0.25 M barium acetate running buffer, pH 5.0. Titan III-H cellulose acetate plate (6.0 × 7.5 cm, Helena BioSciences) was first soaked in distilled H2O for about 1.5 cm and immediately blotted between filter papers. Then, the opposite end was soaked in 0.1 M barium acetate buffer, pH 5.0, for 5.5 cm, leaving a narrow band (2–4 mm large), apparently dry, where 5 μg as uronic acid of each sample was loaded. Electrophoresis was carried out at 5 mA for about 6 minutes followed by incubation of the plate in 0.1 M barium acetate buffer, pH 5.0, for 2 minutes. The second electrophoretic step was carried out at 15 mA for 14 minutes. Subsequently, the plate was soaked in 0.1 M barium acetate buffer, pH 5.0, containing 15% (v/v) ethanol for 2 minutes. A third electrophoretic step was carried out at 12 mA for 17 minutes. Finally, electrophoretic profiles were detected following 0.1% (w/v) Alcian Blue staining. Images were acquired by means of GS-800 calibrated densitometer (Bio-Rad) at 63 μm resolution.

The GAGs/bikunin fractions were assessed for both urine bikunin protein content and presence of urine bikunin fragments by performing SDS-PAGE followed by highly sensitive Coomassie Brilliant Blue G-250 staining (limit of detection: 20 ng of protein) [23] on untreated samples and after chondroitin ABC lyase digestion. The latter was performed in a buffer containing 0.1 M ammonium acetate (pH 8.0) using 0.1 U of chondroitin ABC lyase (Sigma Aldrich) per 100 μg of hexuronate at 37°C overnight. Samples were added with 4X SDS-buffer containing 250 mM Tris (pH 6.8), 8% SDS (w/v), 8% DTT (w/v), 40% glycerol (v/v), and 0.0008% bromophenol blue (w/v) and boiled for 5 minutes before electrophoresis. Urine bikunin was resolved by Tris-glycine SDS-PAGE in 1 mm thick 15% T, 3% C running gel, using a MiniProtean II cell vertical slab gel electrophoresis apparatus (Bio-Rad). Electrophoresis was carried out at 50 V for 15 minutes and subsequently at 150 V until the bromophenol dye front reached the lower limit of the gel. Then, gels were fixed in 30% ethanol (v/v), 2% phosphoric acid (v/v) for 1 h, washed twice in 2% phosphoric acid (v/v) for 10 minutes, equilibrated in 18% ethanol (v/v), 2% phosphoric acid (v/v), and 15% ammonium sulfate (w/v) for 30 minutes, and stained in the same solution containing 0.02% Coomassie Brilliant Blue G-250 (w/v) for 48 h. Gel images were acquired by using GS-800 calibrated densitometer (Bio-Rad) at 63 μm resolution.

2.4. Statistical Analysis. Student’s t-test for unpaired samples was used to compare plasma and urinary GAGs levels between Fabry’s patients and control subjects, using
levels not significantly different from controls (major differences found had to be ascribed to the occurrence of patients as mentioned previously, it was evident that the occurrence of renal damage since NRD patients showed urinary GAGs levels not significantly different from controls ($P = 0.99$). The patients group showed quite different electrophoretic profiles with respect to controls (Table 2, Figure 2). After integration, quali-quantitative results evidenced levels of urine bikunin 2.8 times higher in the patients group in respect to controls ($P = 0.005$). Notably, this difference was significant for RD patients only, who showed about 3.8 times higher levels of urine bikunin as compared with control subjects ($P = 0.0001$). To evaluate if urine bikunin levels in RD patients were associated with the degree of renal impairment, the results for RD patients were analyzed after sorting the group in RD patients with only proteinuria (early renal impairment) and RD patients with overt renal damage (Table 3, Figure 3). In this respect, no major differences were evidenced either in GAGs/bikunin levels or in their distribution among the two subgroups, indicating that the increase of bikunin excretion in RD patients is likely an early biochemical event that occurs at the onset of renal impairment. In order to verify if urine bikunin was in its intact form, we performed SDS-PAGE analysis on GAGs/bikunin fractions as a whole and after chondroitin sulfate removal by chondroitin ABC lyase treatment. In this respect, no significant bikunin fragmentation was evidenced in urine samples from either patients or controls (Figure 4). Furthermore, the SDS-PAGE analysis allowed confirming the higher urine bikunin levels in RD patients.

To rule out the possibility that higher urine bikunin levels in patients could be ascribed, at least partly, to higher levels of plasma bikunin, we assayed plasma CS isomers by FACE analysis evidencing no differences in either plasma CS levels or charge density between patients and control subjects (Table 4, Figures 5 and 6). Furthermore, no correlation between plasma CS and urine bikunin levels (Figure 7) or between serum creatinine and urine bikunin levels was found suggesting a direct kidney involvement in the higher UTI excretion of Fabry’s patients. In absence of overt infection, eleven FD patients out of twenty-four (45.8%) presented with at least one marker of inflammation altered in serum (ESR or CRP, or α-1 and α-2 globulins). These markers were altered in only 10% of controls.

### 3. Results

Quali-quantitative GAGs analyses were conducted in plasma and urine from 24 Fabry’s patients and 43 control subjects. Patients were sorted in RD patients, either with only proteinuria ($n = 5$) or with overt renal damage ($n = 6$), and NRD patients, with no evidence of chronic renal damage ($n = 13$). Qualitative analysis by electrophoresis on cellulose acetate (Figure 1) followed by image analysis allowed evaluating percentages of each purified urinary glycosaminoglycan/proteoglycan, namely, urine bikunin (UTI), HS, and CS. Quali-quantitative results with regard to urine are reported in Table 2 and Figure 2. Hexuronate content analysis evidenced higher urinary GAGs levels (+48%) in patients group in respect to controls ($P = 0.03$). After sorting the group of patients as mentioned previously, it was evident that the major differences found had to be ascribed to the occurrence of renal damage since NRD patients showed urinary GAGs levels not significantly different from controls ($P = 0.99$). The patients group showed quite different electrophoretic profiles with respect to controls (Table 2, Figure 2). After integration, quali-quantitative results evidenced levels of urine bikunin 2.8 times higher in the patients group in respect to controls ($P = 0.005$). Notably, this difference was significant for RD patients only, who showed about 3.8 times higher levels of urine bikunin as compared with control subjects ($P = 0.0001$). To evaluate if urine bikunin levels in RD patients were associated with the degree of renal impairment, the results for RD patients were analyzed after sorting the group in RD patients with only proteinuria (early renal impairment) and RD patients with overt renal damage (Table 3, Figure 3). In this respect, no major differences were evidenced either in GAGs/bikunin levels or in their distribution among the two subgroups, indicating that the increase of bikunin excretion in RD patients is likely an early biochemical event that occurs at the onset of renal impairment. In order to verify if urine bikunin was in its intact form, we performed SDS-PAGE analysis on GAGs/bikunin fractions as a whole and after chondroitin sulfate removal by chondroitin ABC lyase treatment. In this respect, no significant bikunin fragmentation was evidenced in urine samples from either patients or controls (Figure 4). Furthermore, the SDS-PAGE analysis allowed confirming the higher urine bikunin levels in RD patients.

To rule out the possibility that higher urine bikunin levels in patients could be ascribed, at least partly, to higher levels of plasma bikunin, we assayed plasma CS isomers by FACE analysis evidencing no differences in either plasma CS levels or charge density between patients and control subjects (Table 4, Figures 5 and 6). Furthermore, no correlation between plasma CS and urine bikunin levels (Figure 7) or between serum creatinine and urine bikunin levels was found suggesting a direct kidney involvement in the higher UTI excretion of Fabry’s patients. In absence of overt infection, eleven FD patients out of twenty-four (45.8%) presented with at least one marker of inflammation altered in serum (ESR or CRP, or α-1 and α-2 globulins). These markers were altered in only 10% of controls.

### 4. Discussion

Fabry’s disease is a multisystemic disorder in which progressive renal impairment, along with cardiac and central nervous system involvement, plays a major role in lowering life quality and expectancy [3, 4]. In a retrospective study on Fabry’s patients with renal involvement, Branton et al. showed that 50% of patients had proteinuria by 35 years of age and 100% by 52 years of age [24]. Moreover, 50% of male patients presented with chronic renal insufficiency (CRI) by 42 years of age. These authors evidenced that after the development of CRI, there was a rapid decline in glomerular filtration rate leading to end-stage renal disease within 4.1 years. The enzyme replacement therapy (ERT) seems to represent a valid tool to partly counteract the natural progression of Fabry’s disease in combination with renoprotective treatments, such as ACE inhibitors, which are known to be effective in slowing disease progression in other chronic proteinuric kidney diseases [25, 26]. It has also been shown that ERT may be effective in preserving normal renal function in children [27]. Nevertheless, in FD, the diagnosis of an early renal dysfunction is likely of primary importance to aid the clinician in decision making, in designing therapeutic interventions, and in following the natural disease progression or the effects of specific treatments [28].

This paper is the first report to point out that urine bikunin levels are significantly higher in FD patients with renal impairment compared to healthy controls. This finding suggests that the amount of this proteoglycan in urine, as well as proteinuria, could represent an early biomarker of renal impairment in Fabry’s patients, useful in monitoring renal functionality also in those patients without overt renal damage.

Interestingly, in our study also several FD patients treated with ERT showed elevated levels of bikunin in urine.
Table 2: Urine GAGs/UTI levels and distribution in Fabry’s patients and healthy control subjects.

|                      | All patients (n = 24) | RD Patients (n = 11) | NRD Patients (n = 13) | Controls (n = 43) | All patients versus Controls (P) | RD Patients versus NRD patients (P) | RD Patients versus Controls (P) | NRD Patients versus Controls (P) |
|----------------------|-----------------------|----------------------|-----------------------|------------------|---------------------------------|------------------------------------|---------------------------------|---------------------------------|
| Uronic acid (μgUA/mg Cr) | 3.83 ± 1.69           | 4.61 ± 1.63          | 2.60 ± 0.88           | 2.59 ± 1.59      | 0.03                            | 0.009                              | 0.004                           | 0.99                            |
| UTI (%)              | 52.8 ± 20.9           | 63.2 ± 18.3          | 36.6 ± 12.9           | 28.5 ± 17.6      | 0.0009                          | 0.004                             | <0.0001                         | 0.29                            |
| HS (%)               | 20.1 ± 9.1            | 17.4 ± 10.0          | 24.4 ± 5.6            | 30.3 ± 9.3       | 0.003                           | 0.113                             | 0.002                           | 0.14                            |
| CS (%)               | 27.0 ± 14.4           | 19.4 ± 9.0           | 39.0 ± 13.2           | 41.2 ± 11.9      | 0.004                           | 0.002                             | <0.0001                         | 0.70                            |
| UTI (μgUA/mg Cr)     | 2.29 ± 1.79           | 3.15 ± 1.79          | 0.93 ± 0.44           | 0.82 ± 0.81      | 0.005                           | 0.006                             | 0.0001                          | 0.74                            |
| HS (μgUA/mg Cr)      | 0.66 ± 0.26           | 0.67 ± 0.28          | 0.63 ± 0.24           | 0.72 ± 0.37      | 0.57                            | 0.77                               | 0.71                            | 0.58                            |
| CS (μgUA/mg Cr)      | 0.89 ± 0.36           | 0.79 ± 0.23          | 1.03 ± 0.50           | 1.04 ± 0.65      | 0.38                            | 0.18                               | 0.23                            | 0.97                            |

GAGs/PGs levels are reported as μg of uronic acid (UA) per mg of creatinine.
UTI, HS and CS levels are calculated from total UA content and relative percentages of each GAG.
RD: renal disease (proteinuria/renal damage); NRD: no-renal disease.
Significant differences are reported in bold (P < 0.05).

Although in this study we did not plan a formal design aimed to evaluate the urinary bikunin levels at baseline and after a period of ERT, this finding may be supportive of several clinical data indicating that ERT may change significantly the natural progression of the disease if started before the establishment of irreversible organ lesion [25, 29].

Plasma and urine levels of bikunin are related to its anti-inflammatory activity [18], and several studies have associated high plasma and/or urine levels of this proteoglycan with various diseases exhibiting chronic inflammation [11–16]. Notably, several clinical and laboratory findings, as the occurrence of episodic and unexplained fever in some patients with FD, and/or the increased serum levels of ESR, CRP, and α1- and α2-globulin (observed also in 45.8% of our patients with FD) indicate the likely occurrence of both systemic and local inflammation in this pathology [30, 31]. The activation of the inflammatory biochemical pathways in FD, as it may occur in other lysosomal storage disorders (LSDs), is probably related to secondary inappropriate activation of the immune system, in response to storage, resulting in chronic inflammation [32, 33]. It is noteworthy that in LSDs, the occurrence of systemic inflammation contributes to pathogenesis, predates the onset of clinical signs, and may determine the appearance in plasma and/or urine of secondary metabolites which may act as biomarkers that could be useful in following disease progression and may become a target for adjunctive therapy [32, 33]. Importantly, in FD, the ERT is frequently only partially effective in many patients, either due to a late start of this therapy or because of the secondary activation of biochemical mechanisms other than glycosphingolipids storage that also contribute to the pathogenesis of FD. A better understanding of the secondary biochemical pathways involved in FD pathogenesis, as the ones involved in chronic inflammation, may foster the discovery of new therapeutic
Table 3: Urinary glycosaminoglycans/UTI levels and distribution in Fabry’s patients presenting with either only proteinuria or renal damage.

|                      | RD Patients with proteinuria (n = 5) | RD Patients with renal damage (n = 6) | (P) |
|----------------------|--------------------------------------|--------------------------------------|-----|
| Uronic acid (µgUA/mg Cr) | 4.08 ± 1.40                          | 4.91 ± 1.77                          | 0.44|
| UTI (%)              | 52.7 ± 13.6                           | 69.2 ± 18.8                          | 0.16|
| HS (%)               | 23.8 ± 8.9                            | 13.8 ± 9.2                           | 0.11|
| CS (%)               | 23.5 ± 4.8                            | 17.0 ± 10.3                          | 0.27|
| UTI (µgUA/mg Cr)     | 2.27 ± 1.19                           | 3.64 ± 1.96                          | 0.24|
| HS (µgUA/mg Cr)      | 0.88 ± 0.07                           | 0.55 ± 0.29                          | 0.05|
| CS (µgUA/mg Cr)      | 0.92 ± 0.21                           | 0.72 ± 0.22                          | 0.18|

GAGs/PGs levels are reported as µg of uronic acid (UA) per mg of creatinine. UTI, HS and CS levels are calculated from total UA content and relative percentages of each GAG.

Figure 3: Diagrams reporting percentages (a) and levels (b) of urinary trypsin inhibitor (UTI), heparan sulfate (HS), and chondroitin sulfate (CS) in RD patients with proteinuria and RD patients with renal damage. UA: uronic acid.

Table 4: Plasma CS isomers levels and structure in Fabry’s patients and healthy control subjects obtained by FACE analysis of fluorophore-labeled unsaturated disaccharides.

|                      | Patients (n = 24) | Controls (n = 43) | Patients versus Controls (P) |
|----------------------|------------------|------------------|-----------------------------|
| CS isomers (µgUA/mL plasma) | 6.07 ± 2.96      | 5.61 ± 2.99      | 0.66                        |
| * CS charge density (%)       | 41.9 ± 5.9       | 42.8 ± 8.6       | 0.72                        |

* CS charge density was evaluated as ratio between ΔDi-4S and the sum of ΔDi-nonS and ΔDi-4S.

approaches, adjunctive to ERT, potentially of benefit in this pathology.

Since in our Fabry’s patients no correlation was found between plasma CS and urine bikunin levels and no differences were evidenced in plasma CS level/structure between patients and controls, the origin of higher levels of bikunin in urine may imply a direct kidney involvement. Recent RT-PCR analysis studies documenting that several human organs, including the kidney, express bikunin fit this possibility [34]. Moreover, no significant correlation was found between urine bikunin levels and serum creatinine; thus the only impairment of renal function in FD patients seems insufficient to explain higher urine bikunin levels. Nevertheless, the origin of urine bikunin levels and the mechanisms by which urine levels are elevated in our Fabry’s patients remains unclear and need to be further evaluated.

5. Conclusions

Our data indicate that urine bikunin levels may be an early biomarker of renal impairment in patients with FD. Moreover, higher urine levels of this secondary metabolite in FD patients suggest the secondary activation, in response to glycosphingolipids storage, of biochemical pathways related to inflammation. Further studies are necessary to test our
Figure 4: Representative SDS PAGE profiles of nontreated (lane 1) and Chase ABC-treated GAGs-containing fractions from controls (lane 2). Chase ABC-treated GAGs-containing fractions from controls (lane 3), NRD patients (lane 4), RD patients with proteinuria (lane 5), and RD patients with renal damage (lane 6). In lanes 3, 4, 5, and 6, aliquots corresponding to 2 mg of creatinine were loaded. Ovals indicate intact UTI (lane 1) and UTI depleted of chondroitin sulfate chains (lane 2). ST: molecular weight standards (kDa).

Figure 5: Representative FACE profiles of fluorophore-labeled unsaturated disaccharides (ΔDi) obtained from plasma CS isomers of both controls (lane 2) and Fabry’s patients (lane 3). Lane 1: mixture of commercial standard ΔDi (ΔDi-nonS_HA, 2-acetamido-2-deoxy-3-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-4-D-glucose; ΔDi-nonS_CS, 2-acetamido-2-deoxy-3-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-4-D-galactose; ΔDi-6S, 2-acetamido-2-deoxy-3-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-6-O-sulpho-D-galactose; ΔDi-4S, 2-acetamido-2-deoxy-3-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-4-O-sulpho-D-galactose; ΔDi-mono2S, 2-acetamido-2-deoxy-3-O-(4-deoxy-2-O-sulpho-α-L-threo-hex-4-enepyranosyluronic acid)-D-galactose; ΔDi-di(4,6)S, 2-acetamido-2-deoxy-3-O-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-4,6-O-sulpho-D-galactose).
findings in a larger cohort of FD patients and to investigate any existing correlation between urine bikunin levels, progression of FD, and changes in response to ERT.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This study was supported by Regione Autonoma della Sardegna (P.O.R. Sardegna F.S.E. 2007/2013, Asse IV Capitale Umano, Obiettivo operativo I.3-Linea di attivit`a I.3.1) and a free research grant from Shire Italy-Human Genetic Therapies Unit.

References

[1] Y. A. Zarate and R. J. Hopkin, “Fabry’s disease,” The Lancet, vol. 372, no. 9647, pp. 1427–1435, 2008.

[2] R. J. Desnick and R. O. Brady, “Fabry disease in childhood,” Journal of Pediatrics, vol. 144, no. 5, Supplement, pp. S20–S26, 2004.

[3] F. Breunig and C. Wanner, “Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy,” Journal of Nephrology, vol. 21, no. 1, pp. 32–37, 2008.

[4] R. Schifffmann, “Fabry disease,” Pharmacology and Therapeutics, vol. 122, no. 1, pp. 65–77, 2009.

[5] M. Torralba-Cabeza, S. Olivera, D. A. Hughes, G. M. Pastores, R. N. Mateo, and J. Pérez-Calvo, “Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease,” Molecular Genetics and Metabolism, vol. 104, no. 3, pp. 301–307, 2011.

[6] J. D. Esko, K. Kimata, and U. Lindahl, “Proteoglycans and sulfated glycosaminoglycans,” in Essential of Glycobiology, A. Varikis, R. D. Cummings, J. D. Esko et al., Eds., Chapter 16, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2nd edition, 2009.

[7] M. Ly, F. E. Leach, T. N. Laremore, T. Toida, L. J. Amster, and R. J. Linhardt, “The proteoglycan bikunin has a defined sequence,” Nature Chemical Biology, vol. 7, no. 11, pp. 827–833, 2011.

[8] A. Zinellu, S. Pisanu, E. Zinellu et al., “A novel LIF-CE method for the separation of hyalurunan- and chondroitin sulfate-derived disaccharides: application to structural and quantitative analyses of human plasma low- and high-charged chondroitin sulfate isomers,” Electrophoresis, vol. 28, no. 14, pp. 2439–2447, 2007.

[9] E. Zinellu, A. J. Lepedda, A. Cigliano et al., “Association between human plasma chondroitin sulfate isomers and carotid atherosclerotic plaques,” Biochemistry Research International, vol. 2012, Article ID 281284, 6 pages, 2012.

[10] L. Zhuo, V. C. Hascall, and K. Kimata, “Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan- protein complex,” Journal of Biological Chemistry, vol. 279, no. 37, pp. 38079–38082, 2004.

[11] H. Matsuzaki, H. Kobayashi, T. Yagyu et al., “Plasma bikunin as a favorable prognostic factor in ovarian cancer,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1463–1472, 2005.

[12] P. De Muro, R. Faedda, A. Satta et al., “Urinary glycosaminoglycan composition in chronic glomerulonephritis,” Journal of Nephrology, vol. 18, no. 2, pp. 154–160, 2005.

[13] P. De Muro, R. Faedda, A. E. Satta et al., “Quali-quantitative analysis of urinary glycosaminoglycans for monitoring glomerular inflammatory activity,” Scandinavian Journal of Urology and Nephrology, vol. 41, no. 3, pp. 230–236, 2007.

[14] P. De Muro, R. Faedda, A. Masala et al., “Kidney post-transplant monitoring of urinary glycosaminoglycans/proteoglycans and monokine induced by IFN-γ (MIG),” Clinical and Experimental Medicine, vol. 13, no. 1, pp. 59–65, 2013.

[15] P. De Muro, P. Fresu, G. Tonolo et al., “A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 5, pp. 561–567, 2006.

[16] P. De Muro, R. Faedda, M. Formato et al., “Urinary glycosaminoglycans in patients with systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 19, no. 2, pp. 125–130, 2001.

[17] P. De Muro, G. Capobianco, M. Formato et al., “Glycosaminoglycan and transforming growth factor β1 changes in human plasma and urine during the menstrual cycle, in vitro fertilization treatment, and pregnancy,” Fertility and Sterility, vol. 92, no. 1, pp. 320–327, 2009.
[18] M. J. Pugia, R. Valdes Jr., and S. A. Jortani, “Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement,” *Advances in Clinical Chemistry*, vol. 44, pp. 223–245, 2007.

[19] S. De Lin, R. Endo, H. Kuroda et al., “Plasma and urine levels of urinary trypsirina inhibitor in patients with chronic liver diseases and hepatocellular carcinoma,” *Journal of Gastroenterology and Hepatology*, vol. 19, no. 3, pp. 327–332, 2004.

[20] K. Sakai, H. Okudera, and K. Hongo, “Significant elevation of urinary trypsin inhibitor in patients with brain contusion—a preliminary report,” *Journal of Clinical Neuroscience*, vol. 10, no. 6, pp. 677–679, 2003.

[21] T. Bitter and H. M. Muir, “A modified uronic acid carbazole reaction,” *Analytical Biochemistry*, vol. 4, no. 4, pp. 330–334, 1962.

[22] R. Cappelletti, M. Del Rosso, and V. P. Chiarugi, “A new electrophoretic method for the complete separation of all known animal glycosaminoglycans in a monodimensional run,” *Analytical Biochemistry*, vol. 99, no. 2, pp. 311–315, 1979.

[23] A. Zinellu, A. Lepedda Jr., S. Sotgia et al., “Albumin-bound low molecular weight thiols analysis in plasma and carotid plaques by CE,” *Journal of Separation Science*, vol. 33, no. 1, pp. 126–131, 2010.

[24] M. H. Branton, R. Schiffmann, S. G. Sabnis et al., “Natural history of fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course,” *Medicine*, vol. 81, no. 2, pp. 122–138, 2002.

[25] A. Mehta, M. Beck, P. Elliott et al., “Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data,” *The Lancet*, vol. 374, no. 9706, pp. 1986–1996, 2009.

[26] D. G. Warnock and M. L. West, “Diagnosis and management of kidney involvement in fabry disease,” *Advances in Chronic Kidney Disease*, vol. 13, no. 2, pp. 138–147, 2006.

[27] R. Schiffmann, S. Waldek, A. Benigni, and C. Auray-Blais, “Biomarkers of fabry disease nephropathy,” *Clinical Journal of the American Society of Nephrology*, vol. 5, no. 2, pp. 360–364, 2010.

[28] E. Ortu, L. Fancellu, G. Sau et al., “Primary motor cortex hyperexcitability in Fabry’s disease,” *Clinical Neurophysiology*, 2013.

[29] A. C. Vedder, É. Biró, J. M. F. G. Aerts, R. Nieuwland, G. Sturk, and C. E. M. Hollak, “Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment,” *Nephrology Dialysis Transplantation*, vol. 24, no. 10, pp. 3074–3081, 2009.

[30] Y. Kikumoto, Y. Kai, H. Morinaga et al., “Fabry disease exhibiting recurrent stroke and persistent inflammation,” *Internal Medicine*, vol. 49, no. 20, pp. 2247–2252, 2010.

[31] A. H. Futerman and G. Van Meer, “The cell biology of lysosomal storage disorders,” *Nature Reviews Molecular Cell Biology*, vol. 5, no. 7, pp. 554–565, 2004.

[32] E. B. Vitner, F. M. Platt, and A. H. Futerman, “Common and uncommon pathogenic cascades in lysosomal storage diseases,” *Journal of Biological Chemistry*, vol. 285, no. 27, pp. 20423–20427, 2010.

[33] H. Itoh, M. Tomita, T. Kobayashi, H. Uchino, H. Maruyama, and Y. Nawa, “Expression of inter-α-trypsin inhibitor light chain (bikunin) in human pancreas,” *Journal of Biochemistry*, vol. 120, no. 2, pp. 271–275, 1996.